STOCK TITAN

Natera Announces First Quarter 2022 Earnings Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Natera, a leader in cell-free DNA testing, will release its Q1 2022 financial results on May 5, 2022, after market close. A conference call will follow at 1:30 PM PT to discuss these results and future outlook. The company's operations span oncology, women's health, and organ health, supported by over 100 peer-reviewed studies affirming their test accuracy. Natera is committed to integrating personalized genetic testing into standard care, thereby enhancing patient health.

Positive
  • Company is a leader in cell-free DNA testing with a strong focus on oncology and women's health.
  • Natera's tests are supported by over 100 peer-reviewed publications ensuring high accuracy.
Negative
  • None.

AUSTIN, Texas, May 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2022, after the market close on May 5, 2022. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.

Earnings Conference Call Information:

Event:

Natera's First Quarter 2022 Financial Results Conference Call

Date:

Thursday, May 5, 2022

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

(877) 823-0171, Domestic


(617) 500-6932, International

Password:

9390955

Webcast:

https://edge.media-server.com/mmc/p/jtnp5swk

A webcast replay will be available at investor.natera.com.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350

Media: Kate Stabrawa, Communications, Natera, Inc., pr@natera.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/natera-announces-first-quarter-2022-earnings-conference-call-301536935.html

SOURCE Natera, Inc.

FAQ

When will Natera release its Q1 2022 results?

Natera will release its Q1 2022 results on May 5, 2022.

What time is Natera's earnings conference call?

Natera's earnings conference call is scheduled for 1:30 PM PT on May 5, 2022.

What topics will be discussed in Natera's upcoming conference call?

The conference call will cover Natera's financial results, business activities, and financial outlook.

What is the focus of Natera's testing services?

Natera focuses on cell-free DNA testing in oncology, women's health, and organ health.

How is Natera's testing accuracy validated?

Natera's tests are validated by over 100 peer-reviewed publications.

Natera, Inc.

NASDAQ:NTRA

NTRA Rankings

NTRA Latest News

NTRA Stock Data

21.41B
126.56M
3.52%
93.94%
2.83%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
AUSTIN